Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Interview · July 13, 2022

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone as Induction Therapy for High-Risk Transplant-Eligible Patients With Multiple Myeloma

Rafael Fonseca MD
Interview with
Rafael Fonseca MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rafael Fonseca MD

Further Reading

Related Videos